サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1785958

細胞出発材料の世界市場

Cellular Starting Materials

出版日
ページ情報
英文 220 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
細胞出発材料の世界市場
出版日: 2025年08月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 220 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞出発材料の世界市場は2030年までに50億米ドルに達する見込み

2024年に15億米ドルと推定される細胞出発材料の世界市場は、2024～2030年の分析期間でCAGR 21.9%で成長し、2030年には50億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるセルラー・スターティング・ロイコパックスは、CAGR 25.5%を記録し、分析期間終了までに34億米ドルに達すると予測されます。Cellular Starting Cells &Tissuesセグメントの成長率は、分析期間中CAGR 16.3%と推定されます。

米国市場は推定4億300万米ドル、中国はCAGR20.5％で成長予測

米国の細胞出発材料市場は、2024年に4億300万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億6,080万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは20.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ20.5％と18.4％と予測されています。欧州では、ドイツがCAGR約14.6%で成長すると予測されています。

世界の細胞出発材料市場- 主要動向と促進要因のまとめ

細胞出発材料はどのようにバイオテクノロジーに革命を起こしているのか？

細胞出発材料は、細胞治療、再生医療、ワクチン開発など、幅広いバイオ医薬品アプリケーションの基盤となっています。幹細胞、初代細胞、細胞株などを含むこれらの材料は、科学研究を推進し、がん、自己免疫疾患、神経変性疾患などの疾患に対する革新的な治療法を生み出すために不可欠です。プレシジョン・メディシンの急速な拡大に伴い、高品質で十分に特性化された細胞出発材料の需要が高まっています。バイオテクノロジーと遺伝子工学の進歩は、細胞出発材料の拡張性と再現性をさらに向上させました。細胞培養技術、バイオプロセシング技術、凍結保存法における革新は、これらの材料の安定性と生存性を確保し、研究や治療への応用の信頼性を高めています。製薬およびバイオテクノロジー分野が進化し続ける中、細胞出発材料は次世代医療の開発に不可欠なものとなっています。

なぜ細胞出発材料の需要が増えているのか？

慢性疾患や遺伝性疾患の増加により、先進的な細胞ベースの治療法の必要性が高まっており、細胞出発材料の需要に拍車をかけています。研究開発者は、特定の遺伝子経路や分子経路を標的とすることで、患者の予後を改善する個別化治療を開発するために、これらの材料を活用しています。幹細胞治療や組織工学を含む再生医療への注目の高まりは、市場拡大にさらに貢献しています。さらに、細胞免疫療法、遺伝子治療、ワクチン製造の分野における臨床試験の増加により、標準化され倫理的に調達された細胞出発材料に対する需要が高まっています。規制機関は細胞材料調達における品質管理とトレーサビリティを重視しており、調達、検証、保管技術の進歩につながっています。細胞ベースの研究が新たな治療領域に拡大するにつれ、信頼性が高く拡張性のある細胞出発材料の必要性は高まり続けるであろう。

細胞出発材料市場をリードしている地域は？

北米は現在細胞出発材料の最大市場であり、バイオテクノロジーへの旺盛な投資、確立された製薬産業、生物医学研究に対する政府の広範な支援によって牽引されています。米国は細胞ベースの治療開発でリードしており、多数のバイオテクノロジー企業や研究機関が新規細胞ベースの治療開発に積極的に取り組んでいます。ドイツ、英国、フランスなどの国々が細胞治療や再生医療で大きな進歩を遂げており、欧州がこれに続いています。欧州医薬品庁（EMA）は細胞ベースの治療法に関する規制の枠組みの確立に積極的に関与しており、市場の成長をさらに強化しています。一方、アジア太平洋地域は、政府のイニシアチブの増加、ヘルスケア支出の増加、日本、中国、韓国での臨床試験数の増加により、急速な拡大を経験しています。これらの地域では、細胞ベースの研究や治療法の採用が増加しており、市場の大幅な成長が見込まれています。

市場成長を牽引する主な要因とは？

細胞出発材料市場の成長は、幹細胞研究の進展、細胞ベースの治療法の採用増加、再生医療に対する需要の高まりなど、いくつかの要因によってもたらされます。細胞培養と品質管理プロセスにおける人工知能（AI）と自動化の統合は、効率性と拡張性を向上させ、細胞出発材料を研究や治療用途により利用しやすくしています。さらに、バイオ医薬品製造能力の拡大と精密医療への関心の高まりが、高品質の細胞出発材料の需要を促進しています。研究機関、バイオテクノロジー企業、製薬企業間の戦略的提携の増加は、市場の成長をさらに加速させています。細胞ベースの治療が主流になるにつれて、信頼性が高く倫理的に調達された細胞出発材料の需要は増加し、バイオ医薬品イノベーションの将来を形成すると予想されます。

セグメント

製品（細胞出発ロイコパック、細胞出発細胞・組織）、グレード（適正製造基準グレード、研究用グレード）、エンドユーザー（製薬・バイオテクノロジー企業エンドユーザー、学術・研究機関エンドユーザー、CMO・CROエンドユーザー）

調査対象企業の例

  • AcceGen
  • AllCells
  • Anthony Nolan
  • ATCC（American Type Culture Collection）
  • BioIVT
  • Bio-Rad Laboratories, Inc.
  • Biospherix
  • CellGenix
  • CGT GLOBAL
  • Charles River Laboratories
  • Corning Incorporated
  • Excellos
  • Fisher Scientific
  • GE Healthcare（Cytiva）
  • Haplogen GmbH
  • HumanCells Bio
  • Lonza Group
  • Medpace
  • Merck KGaA
  • NMDP BioTherapies

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29881

Global Cellular Starting Materials Market to Reach US$5.0 Billion by 2030

The global market for Cellular Starting Materials estimated at US$1.5 Billion in the year 2024, is expected to reach US$5.0 Billion by 2030, growing at a CAGR of 21.9% over the analysis period 2024-2030. Cellular Starting Leukopaks, one of the segments analyzed in the report, is expected to record a 25.5% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Cellular Starting Cells & Tissues segment is estimated at 16.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$403.0 Million While China is Forecast to Grow at 20.5% CAGR

The Cellular Starting Materials market in the U.S. is estimated at US$403.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$760.8 Million by the year 2030 trailing a CAGR of 20.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 20.5% and 18.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Global Cellular Starting Materials Market - Key Trends & Drivers Summarized

How Are Cellular Starting Materials Revolutionizing Biotechnology?

Cellular starting materials serve as the foundation for a wide range of biopharmaceutical applications, including cell therapy, regenerative medicine, and vaccine development. These materials, which include stem cells, primary cells, and cell lines, are critical for advancing scientific research and producing innovative therapies for diseases such as cancer, autoimmune disorders, and neurodegenerative conditions. With the rapid expansion of precision medicine, the demand for high-quality and well-characterized cellular starting materials is increasing. Advancements in biotechnology and genetic engineering have further improved the scalability and reproducibility of cellular starting materials. Innovations in cell culture techniques, bioprocessing technologies, and cryopreservation methods are ensuring the stability and viability of these materials, making them more reliable for research and therapeutic applications. As the pharmaceutical and biotechnology sectors continue to evolve, cellular starting materials are becoming indispensable in the development of next-generation medical treatments.

Why Is the Demand for Cellular Starting Materials Increasing?

The rising prevalence of chronic and genetic diseases is driving the need for advanced cell-based therapies, fueling the demand for cellular starting materials. Researchers are leveraging these materials to develop personalized treatments that enhance patient outcomes by targeting specific genetic and molecular pathways. The growing focus on regenerative medicine, including stem cell therapies and tissue engineering, is further contributing to market expansion. Moreover, the increasing number of clinical trials in the field of cellular immunotherapy, gene therapy, and vaccine production is amplifying the demand for standardized and ethically sourced cellular starting materials. Regulatory agencies are emphasizing quality control and traceability in cellular material procurement, leading to advancements in sourcing, validation, and storage techniques. As cell-based research expands into new therapeutic areas, the need for reliable and scalable cellular starting materials will continue to grow.

Which Regions Are Leading the Cellular Starting Materials Market?

North America is currently the largest market for cellular starting materials, driven by strong investments in biotechnology, a well-established pharmaceutical industry, and extensive government support for biomedical research. The United States leads in cell-based therapy development, with numerous biotech firms and research institutions actively engaged in developing novel cell-based treatments. Europe follows closely, with countries like Germany, the UK, and France making significant advancements in cell therapy and regenerative medicine. The European Medicines Agency (EMA) has been actively involved in establishing regulatory frameworks for cell-based therapies, further strengthening market growth. Meanwhile, the Asia-Pacific region is experiencing rapid expansion due to increasing government initiatives, rising healthcare expenditures, and a growing number of clinical trials in Japan, China, and South Korea. These regions are expected to drive substantial market growth as cell-based research and therapy adoption increase.

What Are the Key Factors Driving Market Growth?

The growth in the Cellular Starting Materials market is driven by several factors, including advancements in stem cell research, increasing adoption of cell-based therapies, and the rising demand for regenerative medicine. The integration of artificial intelligence (AI) and automation in cell culture and quality control processes is improving efficiency and scalability, making cellular starting materials more accessible for research and therapeutic applications. Additionally, the expansion of biopharmaceutical manufacturing capabilities and the growing focus on precision medicine are propelling demand for high-quality cellular starting materials. The increasing number of strategic collaborations between research institutions, biotech firms, and pharmaceutical companies is further accelerating market growth. As cell-based treatments become more mainstream, the demand for reliable and ethically sourced cellular starting materials is expected to increase, shaping the future of biopharmaceutical innovation.

SCOPE OF STUDY:

The report analyzes the Cellular Starting Materials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Cellular Starting Leukopaks, Cellular Starting Cells and Tissues); Grade (Good Manufacturing Practices Grade, Research-Use Grade); End-Use (Pharmaceutical and Biotechnology Companies End-Use, Academic and Research Institutes End-Use, CMOs and CROs End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AcceGen
  • AllCells
  • Anthony Nolan
  • ATCC (American Type Culture Collection)
  • BioIVT
  • Bio-Rad Laboratories, Inc.
  • Biospherix
  • CellGenix
  • CGT GLOBAL
  • Charles River Laboratories
  • Corning Incorporated
  • Excellos
  • Fisher Scientific
  • GE Healthcare (Cytiva)
  • Haplogen GmbH
  • HumanCells Bio
  • Lonza Group
  • Medpace
  • Merck KGaA
  • NMDP BioTherapies

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cellular Starting Materials - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for High-Quality Starting Materials Propels Cell Therapy and Biomanufacturing Expansion
    • Standardization of Cell Sources Enhances Reproducibility and Downstream Processing
    • Increased Use of iPSCs and Primary Cells Fuels Specialized Starting Material Demand
    • Focus on Cell Line Stability and Genetic Integrity Strengthens Business Case for QC-Compliant Sources
    • Growth in Personalized Medicine Drives Custom and Patient-Derived Material Usage
    • Integration of Closed Systems and Aseptic Handling Enhances Regulatory Readiness
    • Expanding Applications in Immunotherapy and Regenerative Medicine Broadens Material Requirements
    • Strategic Sourcing of Donor-Derived Cells Supports Scale-Up of Allogeneic Therapies
    • Rising Adoption of Xeno-Free and Serum-Free Media Enhances Clinical Viability
    • Advancements in Cryopreservation Techniques Improve Supply Chain Resilience
    • Collaboration Between Biobanks and Therapy Developers Accelerates Commercialization
    • Increased Transparency and Traceability Strengthen GMP Compliance Across Supply Chains
    • Automation in Cell Isolation and Expansion Technologies Supports High-Throughput Needs
    • Growth of Contract Manufacturing Spurs Demand for Consistent Starting Material Supplies
    • Emergence of Ethical and Regulatory Frameworks Promotes Responsible Sourcing Practices
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cellular Starting Materials Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Cellular Starting Materials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Cellular Starting Leukopaks by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Cellular Starting Leukopaks by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cellular Starting Cells & Tissues by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cellular Starting Cells & Tissues by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Good Manufacturing Practices Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Good Manufacturing Practices Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Research-Use Grade by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Research-Use Grade by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for CMOs & CROs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for CMOs & CROs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • JAPAN
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • CHINA
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • EUROPE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Cellular Starting Materials by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Cellular Starting Materials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • FRANCE
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • GERMANY
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Cellular Starting Materials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for Cellular Starting Materials by Product - Cellular Starting Leukopaks and Cellular Starting Cells & Tissues Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of World 15-Year Perspective for Cellular Starting Materials by Product - Percentage Breakdown of Value Sales for Cellular Starting Leukopaks and Cellular Starting Cells & Tissues for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Cellular Starting Materials by Grade - Good Manufacturing Practices Grade and Research-Use Grade Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of World 15-Year Perspective for Cellular Starting Materials by Grade - Percentage Breakdown of Value Sales for Good Manufacturing Practices Grade and Research-Use Grade for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Cellular Starting Materials by End-Use - Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Cellular Starting Materials by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies End-Use, Academic & Research Institutes End-Use and CMOs & CROs End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION